Premium
EBV‐directed viral‐specific T‐lymphocyte therapy for the treatment of EBV‐driven lymphoma in two patients with primary immunodeficiency and DNA repair defects
Author(s) -
Rubinstein Jeremy D.,
Burns Karen,
Absalon Michael,
Lutzko Carolyn,
Leemhuis Tom,
Chandra Sharat,
Hanley Patrick J.,
Keller Michael D.,
Davies Stella M.,
Nelson Adam,
Grimley Michael
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28126
Subject(s) - medicine , lymphoma , primary immunodeficiency , ataxia telangiectasia , immunodeficiency , immunology , toxicity , chemotherapy , lymphocyte , malignancy , virus , virology , immunotherapy , cancer research , dna damage , immune system , dna , biology , genetics
Children with ataxia telangiectasia (AT), a primary immunodeficiency caused by mutations in ATM , which is critical for repairing DNA defects, are at risk for the development of hematologic malignancy, frequently driven by infection with Epstein‐Barr virus (EBV). Conventional chemotherapy is poorly tolerated by patients with AT, with excessive toxicity even when doses are reduced. Here, we report on two patients with AT and EBV‐positive neoplasms who were treated with EBV‐targeted viral‐specific T cells (VST). One patient had a prolonged complete response to VSTs while the other had a partial response. Therapy was well tolerated without infusion toxicity or graft‐versus‐host disease.